1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Pricewatch UK

UK Gabapentin Prices Shoot Up In December

Pricewatch UK – December 2024

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

Price Watch UK
• Source: Alamy

Average UK trade prices for the 600mg tablet presentation of gabapentin shot up in December, rising by almost three times on average, according to the latest figures from market researcher WaveData.

Based on trade prices to UK independent pharmacists, WaveData found that gabapentin 600mg tablets had risen by 195% on average...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricewatch UK

UK Sitagliptin Prices Shoot Up In June

 
• By Dave Wallace

Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.

UK Pioglitazone Prices Go Through The Roof Among A Raft Of May Rises

 
• By Dave Wallace

As multiple molecules experienced triple-digit percentage price rises in May, pioglitazone once again led the way after already topping our table of price increases in April.

Pioglitazone Prices Peak In April As Multiple UK Molecules Double In Price

 
• By Dave Wallace

Diabetes medication pioglitazone topped the list of the fastest-rising UK generics prices in April, according to market researcher WaveData.

Trihexyphenidyl Tablets Treble In A Busy March For UK Price Rises

 
• By Dave Wallace

Trihexyphenidyl tablets in two different strengths led a raft of UK generic price rises in March, according to the latest figures from WaveData.

More from Generics Bulletin

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

 
• By Dean Rudge

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

Samsung Bioepis’ Second Quarter Comes Down From Milestone-Boosted Q2 2024

 
• By Urtė Fultinavičiūtė

With the looming spin-off on the horizon, Samsung Bioepis looks at planned product launches and geographic expansion to maintain its annual revenue growth.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.